RxDoctor Payments Data

Paul McFarlane, MD

Family Medicine · Norwich, CTNPI 1356969653

Payments from drug & device makers

$1,877in general payments, 2019–2025

Across 33 payments — averaging $56.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$620
  • Viiv Healthcare Company$511
  • AbbVie$181
  • Mallinckrodt Hospital Products Inc.$125
  • Pfizer$111
  • Otsuka America Pharmaceutical, Inc.$111
  • plus $219 from 7 others

What the payments were for

  • Food & beverage$1,877100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,877 in reported general payments places this provider in the 75th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$66,944
Medicare patients
294
Services billed
607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$84,066
MounjaroTirzepatide19$20,643
JardianceEmpagliflozin21$20,610
FarxigaDapagliflozin Propanediol19$17,481
TrulicityDulaglutide16$15,661
MyrbetriqMirabegron15$11,709
JanuviaSitagliptin Phosphate12$10,634
Varenicline Tartrate11$5,182
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$4,226
Pregabalin17$3,284
Atorvastatin Calcium220$1,600
Allopurinol27$1,408
Gabapentin73$1,326
SynthroidLevothyroxine Sodium25$1,304
Albuterol Sulfate HfaAlbuterol Sulfate59$1,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$84,06673 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$25$36,66449 claims
AstraZenecaFarxiga$104$17,48119 claims
MerckJanuvia$16$10,63412 claims
AbbVieSynthroid$181$1,30425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →